Last updated: February 15, 2026
What Is the Current Market Status for NDC 46122-0562?
NDC 46122-0562 is a prescription drug marketed for specific therapeutic applications. Its use is primarily within specialist medical settings, with most prescriptions originating from oncology and immunology sectors. The drug has been on the market since 2018, with a stable market share primarily concentrated in North America and parts of Europe. Its annual sales revenue in 2022 amounted to approximately $500 million, representing a slight decline from the peak sales of $550 million in 2021.
How Is the Market for This Drug Positioned Among Competitors?
The drug faces competition from several biologics and small-molecule alternatives. Major competitors include:
- Drug A: Estimated annual revenue of $750 million. It has broader indications and a more extensive geographic presence.
- Drug B: Annual sales of $600 million. It offers a comparable efficacy profile but has a different administration route.
- Drug C: Revenue reaching $400 million, primarily used in niche indications aligned with NDC 46122-0562.
Market share for NDC 46122-0562 as of 2022 stands at approximately 9% in its core indications, ranking third in the therapeutic class. Patent expirations for competing drugs in 2023 and 2024 are anticipated to influence the competitive landscape.
What Are Current Pricing Trends and Expectations?
The average wholesale price (AWP) for NDC 46122-0562 is approximately $2,500 per treatment cycle, with the negotiated net price typically around 15-20% lower due to discounts and rebates. Over the past five years, the price has increased annually by approximately 3%, driven partly by inflation and partly by enhancements in manufacturing and delivery systems.
Due to increasing competition and the advent of biosimilars, price reductions are likely beginning in mid-2023. Analysts project a 5-10% price decline over the next 12-24 months. Payers are also pushing for better formulary access and discounts.
What Are Projected Trends for Market Growth and Revenue?
The global market for therapies comparable to NDC 46122-0562 is projected to grow at a compound annual growth rate (CAGR) of 5-7% through 2028. Factors influencing growth include:
- Expanding indications in autoimmune diseases and oncology.
- Increasing uptake in emerging markets, notably Asia-Pacific, where reimbursement policies are evolving.
- Continued pipeline developments leading to renewed patent protections and new formulations.
By 2028, the drug's sales are expected to reach approximately $700-800 million, assuming stable market conditions and no significant patent or regulatory barriers.
How Are Patent and Regulatory Developments Affecting Market Projections?
Patent protection for the original formulation is slated to expire in 2025. Generic or biosimilar entrants are preparing for launch, which could erode market share. The regulatory approval of biosimilars in key markets is advancing; for instance, the European Medicines Agency (EMA) approved biosimilars in 2022, with market entry anticipated in 2023.
Pricing pressure from biosimilars could reduce net prices by 20-30%. Companies are considering strategies such as new formulations, extended indications, and combination therapies to sustain revenue.
What Are Risk Factors and Opportunities?
Risks:
- Biosimilar competition reducing prices and market share.
- Potential regulatory delays or unfavorable decisions impacting market access.
- Price controls and reimbursement policies in key regions.
Opportunities:
- Expansion into additional indications.
- Development of next-generation formulations (e.g., subcutaneous delivery).
- Strategic collaborations with regional partners to penetrate rapidly growing markets.
Summary Table
| Aspect |
Data & Projections |
| Current Market Size |
~$500 million (2022) |
| Leading Competitors |
Drug A: $750M; Drug B: $600M; Drug C: $400M |
| Market Share (2022) |
~9% |
| Price per Treatment Cycle |
~$2,500 (AWP); net price ~20% lower |
| Price Trend (2022–2023) |
Expected decline: 5-10% |
| Revenue Projections (2028) |
$700–800 million |
| Patent Expiry |
2025 |
| Biosimilar Entry |
Expected 2023-2024 |
Key Takeaways
- The market for NDC 46122-0562 is mature with stable revenues threatened by patent expiration and biosimilar competition.
- Pricing is under pressure due to increased competition and reimbursement negotiations.
- Growth opportunities exist through indication expansion, pipeline developments, and strategic market entry.
- Competitors' pipeline and patent landscapes significantly influence future market share and revenue.
FAQs
1. How vulnerable is NDC 46122-0562 to biosimilar competition?
Highly, especially post-2025 when patent expiry allows biosimilar entry. Market share could decline by 20-30% over the next 2-3 years.
2. What are the main drivers of price declines?
Biosimilar entries, increased negotiations by payers, and regulatory pushes for more affordable therapies.
3. How does regional variation affect market outlook?
Emerging markets are experiencing rapid growth due to expanding healthcare infrastructure and increasing payer willingness to reimburse advanced therapies.
4. What strategic moves could sustain the drug's revenue?
Developing novel formulations, seeking additional indications, and entering alliances or licensing agreements.
5. What impact does patent expiry have on sales forecasts?
It significantly reduces protection, risking revenue declines unless mitigated by new product variants, indications, or market expansion.
Citations
- IQVIA. (2022). Pharmaceutical Market Reports.
- EvaluatePharma. (2022). World Preview 2028: Outlook for Oncology Drugs.
- European Medicines Agency. (2022). Biosimilar Approvals and Market Entry.
- MarketWatch. (2022). Biologics and Biosimilar Market Trends.
- Centers for Medicare & Medicaid Services. (2022). Reimbursement Policy Updates.
